SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-091903
Filing Date
2024-08-06
Accepted
2024-08-06 16:31:25
Documents
54
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ubx-20240630.htm   iXBRL 10-Q 2009766
2 EX-31.1 ubx-ex31_1.htm EX-31.1 16192
3 EX-31.2 ubx-ex31_2.htm EX-31.2 16193
4 EX-32.1 ubx-ex32_1.htm EX-32.1 15125
  Complete submission text file 0000950170-24-091903.txt   7906246

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ubx-20240630.xsd EX-101.SCH 1202038
56 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20240630_htm.xml XML 1349408
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

IRS No.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38470 | Film No.: 241179873
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)